SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SYRE

Spyre Therapeutics, Inc. (SYRE)

NASDAQ: SYRE · Real-Time Price · USD
Healthcare · Biotechnology
$93.81-$5.56 (-5.60%)
 
Market cap
$8.91B
Insider Score
Analyst consensus
Website
Market Cap$8.91B+307.9%
Revenue (ttm)n/a
Net Income-$224.00M
EPS-$2.49
Shares Out94.97M
PE Ration/a
Forward PE-25.40
Dividendn/a
Ex-Dividend Daten/a
Volume1,102,434
Open$98.70
Previous Close$99.37
Day's Range$92.95 - $100.03
52-Week Range$23.01 - $110.64
Beta3.23
AnalystsStrong Buy
Price Target$123.87(+32.04%)
Earnings DateNov 3, 2026

About SYRE

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Address
Building 23, Waltham, MA, 02453, United States
Market Cap
8.91 billion
Employees
130
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$8.61M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $116.83 (+24.5%)

4 firms rating SYRE in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-4.45%
5 Days
-8.83%
1 Month
+24.37%
6 Months
+41.80%
1 Year
+307.92%

$SYRE stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SYRE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SYRE's directors and management

Net Shares Purchased by Insiders−60k−30k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SYRE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

SYRE Revenue by Segment

$53.03MTotal
Stock-based compensation$40.48M76.34%
Compensation$12.55M23.66%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New SYRE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SYRE from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from SYRE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Analyst upgrades and price target increases dominate, offset modestly by one trim; earnings and corporate updates support bullish momentum.

Recent Insider Activity

Buys
0
Sells
23
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-33.0 since Aug 21
0255075100Aug 21 — Insider Score 33.0Aug 22 — Insider Score 33.0Aug 23 — Insider Score 33.0Aug 24 — Insider Score 33.0Aug 25 — Insider Score 33.0Aug 26 — Insider Score 33.0Aug 27 — Insider Score 33.0Aug 28 — Insider Score 34.0Aug 29 — Insider Score 34.0Aug 30 — Insider Score 34.0Aug 31 — Insider Score 34.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 22.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

LFSCF/M Emerald Life Sciences Innovation ETF4.28%
QMOMAlpha Architect U.S. Quantitative Momentum ETF2.57%
TDNAT. Rowe Price Biotech ETF2.10%
XBIState Street SPDR S&P Biotech ETF1.77%
FCMO.TOFidelity U.S. Momentum Index ETF1.47%
MMSCFirst Trust Multi-Manager Small Cap Opportunities ETF1.24%
SGRWHarbor Active Small Cap Growth ETF (SGRW)1.17%
BBCVirtus Biotech Clinical Trials ETF0.98%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.89%
MEDIHarbor Health Care ETF (MEDI)0.78%
GSCGoldman Sachs Small Cap Equity ETF0.75%
ESSCEventide Small Cap ETF0.62%

Weight is the stock’s share of each fund’s holdings.